TY  - BOOK
AU  - Nair, S.
TI  - Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients
PY  - 2017///
N1  - NMUH Staff Publications; 10
N2  - &lt;h4&gt;&lt;span style="font-size: 10pt;"&gt;AIM:&lt;span style="font-weight: normal;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-weight: normal;"&gt;To establish the efficacy and safety of bimatoprost 0.03% monotherapy in glaucoma and ocular hypertension (OHT) patients with inadequate intraocular pressure (IOP)on current therapy.&lt;/span&gt;&lt;/span&gt;&lt;/h4&gt;&lt;h4&gt;&lt;span style="font-size: 10pt;"&gt;METHODS: &lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-weight: normal;"&gt;Pre- and post-switch IOPs were analyzed for 59 consecutive patients who were switched from current therapy to bimatoprost monotherapy between 2011-2015. Demographic information, diagnosis, and any adverse events were recorded. Change in IOP post-pre switch was analyzed using a 2-sided Student's paired &lt;em&gt;t&lt;/em&gt;-test at the 5% significance level.&lt;/span&gt;&lt;/span&gt;&lt;/h4&gt;&lt;h4&gt;&lt;span style="font-size: 10pt;"&gt;RESULTS: &lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-weight: normal;"&gt;There was a statistically significant mean reduction in IOP at the first follow up visit, which was maintained at subsequent follow up visits for patients regardless of diagnosis, or pre-switch treatment (&lt;em&gt;P&lt;/em&gt;&amp;lt;0.001). Subgroup analysis also demonstrated a statistically significant mean reduction in IOP when looking at OHT patients only, as well as patients with any diagnosis switched from latanoprost monotherapy to bimatoprost monotherapy (&lt;em&gt;P&lt;/em&gt;&amp;lt;0.001).&lt;/span&gt;&lt;/span&gt;&lt;/h4&gt;&lt;h4&gt;&lt;span style="font-size: 10pt;"&gt;CONCLUSION: &lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-weight: normal;"&gt;This is the largest independent data set which supports switching glaucoma patients with poor response to current treatment onto bimatoprost monotherapy before considering other adjuvant medical or more invasive therapy.&lt;/span&gt;&lt;/span&gt;&lt;/h4&gt;&amp;nbsp
UR  - https://www.ncbi.nlm.nih.gov/pubmed/28861351
UR  - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5554844/pdf/ijo-10-08-1251.pdf
ER  -